Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taspoglutide versus exenatide in adults with type 2 diabetes inadequately controlled on metformin and/or thiazolidinedione
2008-001856-36Phase 3Terminated
- Sponsor
- Roche
- Start
- Jun 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Taspoglutide with Exenatide BID (2 arms). Primary endpoint: Absolute change from baseline in HbA1c. Started Jun 2008; status: terminated.
02
Drugs
taspoglutideexenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-001856-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001856-36.